The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2024

Filed:

Oct. 05, 2020
Applicants:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Inventors:

Meromit Singer, Boston, MA (US);

Aviv Regev, Cambridge, MA (US);

Orit Rozenblatt-Rosen, Cambridge, MA (US);

Davide Mangani, Boston, MA (US);

Ana Carrizosa Anderson, Boston, MA (US);

Vijay K. Kuchroo, Boston, MA (US);

Linglin Huang, Boston, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/38 (2006.01); C07K 16/40 (2006.01); C12N 5/0783 (2010.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0638 (2013.01); A61K 35/17 (2013.01); A61K 39/39541 (2013.01); A61K 39/3955 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C07K 16/38 (2013.01); C07K 16/40 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/507 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01);
Abstract

The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.


Find Patent Forward Citations

Loading…